A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome

BACKGROUND: Gamma-aminobutyric acid (GABA) system deficits are integral to the pathophysiologic development of fragile X syndrome (FXS). Ganaxolone, a GABA(A) receptor positive allosteric modulator, is hypothesized to improve symptoms such as anxiety, hyperactivity, and attention deficits in childre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligsay, Andrew, Van Dijck, Anke, Nguyen, Danh V., Lozano, Reymundo, Chen, Yanjun, Bickel, Erika S., Hessl, David, Schneider, Andrea, Angkustsiri, Kathleen, Tassone, Flora, Ceulemans, Berten, Kooy, R. Frank, Hagerman, Randi J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540519/
https://www.ncbi.nlm.nih.gov/pubmed/28764646
http://dx.doi.org/10.1186/s11689-017-9207-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540519/
https://www.ncbi.nlm.nih.gov/pubmed/28764646
http://dx.doi.org/10.1186/s11689-017-9207-8

Ejemplares similares